Stock Events

Stock Events

Ginkgo Bioworks

$0.006300

566

-$0.00-37.62% Tuesday 19:58

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

11NovExpected

Q4 2023

Q1 2024

Q2 2024

Q3 2024

-4.4

-2.96

-1.52

-0.08

Expected EPS

-2.740675

Actual EPS

N/A

Financials

-355.08%Profit Margin

Unprofitable

2020

2021

2022

2023

251.46MRevenue

-892.87MNet Income

Analyst Ratings

7.00Average Price Target

The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

0%

Hold

50%

Sell

50%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Twist Bioscience

Twist Bioscience Corporation operates in the synthetic biology field, offering DNA synthesis products that compete with Ginkgo Bioworks' platform for programming cells.

Synlogic, Inc. is engaged in the development of therapeutics that leverage synthetic biology, competing in the biotech space where Ginkgo Bioworks also operates.

Codexis, Inc. specializes in protein engineering and enzyme optimization, competing with Ginkgo Bioworks in the field of bio-catalysis and bio-manufacturing.

Evogene Ltd. applies computational biology and synthetic biology to develop products in agriculture, competing with Ginkgo Bioworks in the agri-biotech sector.

Pacific Biosciences of California

Pacific Biosciences of California, Inc. provides sequencing systems that compete with Ginkgo Bioworks' offerings in the genomics and genetic engineering space.

Illumina, Inc. is a leader in genomics and DNA sequencing technologies, indirectly competing with Ginkgo Bioworks by enabling synthetic biology research and applications.

CRISPR Therapeutics

CRISPR Therapeutics AG focuses on gene editing technologies, competing in the broader biotech space for genetic engineering applications, overlapping with Ginkgo's market.

Editas Medicine

Editas Medicine, Inc. is involved in gene editing, competing in the genetic modification space, which is relevant to Ginkgo Bioworks' synthetic biology applications.

About

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Show more...

CEO

Jason Kelly

Employees

485

Country

United States

ISIN

US37611X1182

Listings

0 Comments

Share your thoughts

FAQ

What is Ginkgo Bioworks stock price today?▼

The current price of DNA-WT is $0.01 USD — it has decreased by -37.62% in the past 24 hours. Watch Ginkgo Bioworks stock price performance more closely on the chart.

What is Ginkgo Bioworks stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Ginkgo Bioworks stocks are traded under the ticker DNA-WT.

What is Ginkgo Bioworks revenue for the last year?▼

Ginkgo Bioworks revenue for the last year amounts to 251.46M USD.

What is Ginkgo Bioworks net income for the last year?▼

DNA-WT net income for the last year is -892.87M USD.

How many employees does Ginkgo Bioworks have?▼

As of August 18, 2026, the company has 485 employees.

In which sector is Ginkgo Bioworks located?▼

Ginkgo Bioworks operates in the Health & Wellness sector.

When did Ginkgo Bioworks complete a stock split?▼

Ginkgo Bioworks has not had any recent stock splits.

Where is Ginkgo Bioworks headquartered?▼

Ginkgo Bioworks is headquartered in BOSTON, United States.